Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Muro, Kei | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Shimada, Yasuhiro | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Yen, Chia-Jui | - |
dc.contributor.author | Chao, Yee | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.contributor.author | Cheng, Rebecca | - |
dc.contributor.author | Carlesi, Roberto | - |
dc.contributor.author | Chandrawansa, Kumari | - |
dc.contributor.author | Orlando, Mauro | - |
dc.contributor.author | Ohtsu, Atsushi | - |
dc.date.accessioned | 2021-09-04T02:20:11Z | - |
dc.date.available | 2021-09-04T02:20:11Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89435 | - |
dc.description.abstract | Background and AimEast Asia has higher gastric cancer incidence and mortality rates than other regions. We present a subgroup analysis of East Asians in the positive study RAINBOW. MethodsPatients with advanced gastric or gastroesophageal junction adenocarcinoma previously treated with platinum and fluoropyrimidine received ramucirumab 8mg/kg or placebo on days 1 and 15 plus paclitaxel 80mg/m(2) on days 1, 8, and 15 of a 28-day cycle. ResultsOf 665 intention-to-treat patients, 223 were East Asian. Median overall survival was 12.1months for ramucirumab plus paclitaxel and 10.5months for placebo plus paclitaxel (hazard ratio: 0.986, 95% confidence interval: 0.727-1.337, P=0.929). Median progression-free survival was 5.5months for ramucirumab plus paclitaxel and 2.8months for placebo plus paclitaxel (hazard ratio: 0.628, 95% confidence interval: 0.473-0.834, P=0.001). Objective response rates were 34% for ramucirumab plus paclitaxel and 20% for placebo plus paclitaxel. Grade 3 neutropenia (60% vs 28%) and leukopenia (34% vs 13%) were higher for ramucirumab plus paclitaxel. The rate of febrile neutropenia was low (4% vs 4%). Special interest adverse events included any grade bleeding/hemorrhage (55% vs 25%), proteinuria (27% vs 7%), and hypertension (22% vs 2%). ConclusionsRamucirumab plus paclitaxel significantly improves progression-free survival and response rate, with prolonged median overall survival and an acceptable safety profile in East Asians with advanced gastric cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | 2ND-LINE CHEMOTHERAPY | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | MANAGEMENT | - |
dc.subject | ETHNICITY | - |
dc.subject | COMBINATION | - |
dc.subject | SURVIVAL | - |
dc.title | Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.1111/jgh.13153 | - |
dc.identifier.scopusid | 2-s2.0-84959094187 | - |
dc.identifier.wosid | 000371483800014 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, v.31, no.3, pp.581 - 589 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.title | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.volume | 31 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 581 | - |
dc.citation.endPage | 589 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | 2ND-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | ETHNICITY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | Far East | - |
dc.subject.keywordAuthor | gastrointestinal neoplasms | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | ramucirumab | - |
dc.subject.keywordAuthor | vascular endothelial growth factor receptor-2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.